Clinical Trial Update: TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir [Phase 1]

View source ↗

Summary

Phase 1 study in healthy volunteers evaluating pharmacokinetic interaction between rilpivirine (TMC278) and raltegravir; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)
• Isentress (Raltegravir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 1 | Status: COMPLETED